See more : Slack Technologies, Inc. (WORK) Income Statement Analysis – Financial Results
Complete financial analysis of Trevena, Inc. (TRVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Trevena, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Success Prime Corporation (2496.TW) Income Statement Analysis – Financial Results
- Encres Dubuit (ALDUB.PA) Income Statement Analysis – Financial Results
- Rite Aid Corporation (RAD) Income Statement Analysis – Financial Results
- Chubb Limited (0VQD.L) Income Statement Analysis – Financial Results
- Jiangsu Boxin Investing&Holdings Co.,Ltd. (600083.SS) Income Statement Analysis – Financial Results
Trevena, Inc. (TRVN)
About Trevena, Inc.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.13M | -418.00K | 567.00K | 3.07M | 31.00K | 5.73M | 0.00 | 3.75M | 6.25M | 0.00 | 134.98K | 807.60K | 2.42M |
| Cost of Revenue | 1.67M | 3.02M | 954.00K | 182.00K | 108.00K | 0.00 | 490.00K | 0.00 | 44.07M | 40.55M | 18.76M | 13.29M | 0.00 |
| Gross Profit | 1.46M | -3.44M | -387.00K | 2.89M | -77.00K | 5.73M | -490.00K | 3.75M | -37.82M | -40.55M | -18.63M | -12.49M | 2.42M |
| Gross Profit Ratio | 46.56% | 822.01% | -68.25% | 94.07% | -248.39% | 100.00% | 0.00% | 100.00% | -605.18% | 0.00% | -13,800.00% | -1,546.24% | 100.00% |
| Research & Development | 16.33M | 18.21M | 13.43M | 13.12M | 13.29M | 15.82M | 48.97M | 89.96M | 44.07M | 40.55M | 18.76M | 13.29M | 15.11M |
| General & Administrative | 0.00 | 0.00 | 38.11M | 19.25M | 13.21M | 18.98M | 19.64M | 16.08M | 12.80M | 9.40M | 4.72M | 3.12M | 3.06M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.41M | 34.73M | 38.11M | 19.25M | 13.21M | 18.98M | 19.64M | 16.08M | 12.80M | 9.40M | 4.72M | 3.12M | 3.06M |
| Other Expenses | 0.00 | 2.71M | 337.00K | 416.00K | 2.25M | 459.00K | 614.00K | -711.00K | 92.93K | 184.02K | 1.25K | 122.79K | 0.00 |
| Operating Expenses | 38.41M | 52.94M | 51.54M | 32.37M | 26.50M | 34.80M | 68.61M | 106.03M | 56.87M | 49.95M | 23.48M | 16.42M | 18.17M |
| Cost & Expenses | 38.41M | 55.96M | 52.49M | 32.55M | 26.50M | 34.80M | 68.61M | 106.03M | 56.87M | 49.95M | 23.48M | 16.42M | 18.17M |
| Interest Income | 2.25M | 451.00K | 162.00K | 240.00K | 418.00K | 1.00M | 679.00K | 743.00K | 331.21K | 17.37K | 884.00 | 754.00 | 3.54K |
| Interest Expense | 0.00 | 1.26M | 1.00K | 29.00K | 931.00K | 2.23M | 2.78M | 1.74M | 334.37K | 70.65K | 149.76K | 193.74K | 74.22K |
| Depreciation & Amortization | 893.00K | 864.00K | 841.00K | 830.00K | 863.00K | 645.00K | 490.00K | 246.00K | 207.90K | 239.39K | 706.78K | 787.52K | 801.58K |
| EBITDA | -35.29M | -55.51M | -51.08M | -28.66M | -25.61M | -28.43M | -68.12M | -101.01M | -50.62M | -49.71M | -22.64M | -14.65M | -14.95M |
| EBITDA Ratio | -1,129.22% | 13,486.84% | -9,157.85% | -960.74% | -74,961.29% | -482.27% | 0.00% | -2,727.55% | -809.94% | 0.00% | -16,770.17% | -1,820.09% | -617.21% |
| Operating Income | -35.29M | -56.38M | -51.93M | -29.49M | -26.58M | -30.50M | -70.39M | -102.28M | -50.62M | -49.95M | -23.35M | -15.61M | -15.75M |
| Operating Income Ratio | -1,129.22% | 13,486.84% | -9,157.85% | -960.74% | -85,741.94% | -532.07% | 0.00% | -2,727.55% | -809.94% | 0.00% | -17,295.37% | -1,932.90% | -650.46% |
| Total Other Income/Expenses | -4.68M | 2.71M | 337.00K | 416.00K | 1.71M | 459.00K | -3.25M | -711.00K | 92.76K | 249.13K | 93.85K | -25.62K | -59.79K |
| Income Before Tax | -39.97M | -53.67M | -51.59M | -29.07M | -24.87M | -30.04M | -71.87M | -102.99M | -50.53M | -49.70M | -23.25M | -15.64M | -15.81M |
| Income Before Tax Ratio | -1,279.07% | 12,839.71% | -9,098.41% | -947.18% | -80,229.03% | -524.06% | 0.00% | -2,746.51% | -808.45% | 0.00% | -17,225.84% | -1,936.08% | -652.93% |
| Income Tax Expense | 318.00K | -2.71K | -428.00K | 300.00K | 3.19M | 745.00K | 3.39M | -246.00K | -207.90K | 254.67K | 151.00K | 316.53K | 74.22K |
| Net Income | -40.29M | -53.67M | -51.16M | -29.37M | -28.06M | -30.78M | -71.87M | -102.99M | -50.53M | -49.70M | -23.25M | -15.64M | -15.81M |
| Net Income Ratio | -1,289.25% | 12,839.07% | -9,022.93% | -956.96% | -90,503.23% | -537.06% | 0.00% | -2,746.51% | -808.45% | 0.00% | -17,225.84% | -1,936.08% | -652.93% |
| EPS | -54.51 | -14.88 | -7.82 | -4.86 | -7.65 | -10.46 | -30.23 | -49.14 | -28.84 | -50.40 | -22.59 | -28.41 | -38.03 |
| EPS Diluted | -54.51 | -14.88 | -7.77 | -4.86 | -7.65 | -10.46 | -30.23 | -49.14 | -28.84 | -50.40 | -22.59 | -28.41 | -38.03 |
| Weighted Avg Shares Out | 739.05K | 3.61M | 6.54M | 6.05M | 3.67M | 2.94M | 2.38M | 2.10M | 1.75M | 986.22K | 1.03M | 550.43K | 415.72K |
| Weighted Avg Shares Out (Dil) | 739.05K | 3.61M | 6.58M | 6.05M | 3.67M | 2.94M | 2.38M | 2.10M | 1.75M | 986.22K | 1.03M | 550.43K | 415.72K |
Trevena Posts TRV027 Proof-of-Concept Study In Hospitalized COVID-19 Patients
Trevena Inc (NASDAQ: TRVN) has announced data from 30 patients enrolled in the proof-of-concept study of TRV027 in hospitalized COVID-19 patients. The results showed that TRV027 was well-tolerated and provided initial evidence of its potential to improve biomarker and clinical endpoints associated with...
Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients
-- 92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality
Trevena to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit
CHESTERBROOK, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief...
Imvax Appoints John M. Limongelli as Chief Legal Officer
PHILADELPHIA--(BUSINESS WIRE)--Imvax announced the appointment of John M. Limongelli as the Company's Chief Legal Officer effective September 16, 2021.
Trevena Announces Two OLINVYK® Abstracts Highlighting Safety Data Accepted at ANESTHESIOLOGY® 2021
CHESTERBROOK, Penn., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the acceptance of two abstracts at...
Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study
-- Study is being led by Cleveland Clinic; designed to evaluate potential benefit of OLINVYK on respiratory, GI, and cognitive function outcomes in postoperative patients
New Strong Sell Stocks for August 20th
ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.
Trevena: Remaining Patient After A Disappointing Q2 Earnings
Trevena recently reported disappointing Q2 earnings that revealed they completely missed the Street's expectations and only pulled in ~$180K in revenue. The COVID-19 headwinds are slamming Trevena and the forecast does not appear to be clearing up. As a result,...
Trevena's (TRVN) CEO Carrie Bourdow on Q2 2021 Results - Earnings Call Transcript
Trevena's (TRVN) CEO Carrie Bourdow on Q2 2021 Results - Earnings Call Transcript
Trevena: Q2 Earnings Insights
Shares of Trevena (NASDAQ:TRVN) rose 0.7% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 50.00% over the past year to ($0.09), which missed the estimate of ($0.07).
Source: https://incomestatements.info
Category: Stock Reports